Stockholm School of Economics

About: Stockholm School of Economics is a education organization based out in Stockholm, Sweden. It is known for research contribution in the topics: Population & Entrepreneurship. The organization has 1186 authors who have published 4891 publications receiving 285543 citations. The organization is also known as: Stockholm Business School & Handelshögskolan i Stockholm.

European unemployment and turbulence revisited in a matching model

Abstract: We recalibrate den Haan, Haefke, and Ramey’ s matching model to incorporate our preferred specie cation of “ turbulence” as causing distinct dynamics of human capital after voluntary and involuntary job losses. Under our calibration, with high unemployment benee ts, an increase in turbulence increases the unemployment rate and the duration of unemployment while leaving the ine ow rate into unemployment roughly unchanged, mirroring features of European data in the 1980s and 1990s. The essential issue is that den Haan, Haefke, and Ramey specify that in turbulent times workers experiencing layoffs and quits are both subject to instantaneous skill losses, while we restrict instantaneous skill losses to laid-off workers. (JEL: E24, J64)

Ain't Misbehavin': Taking Play Seriously in Organizations

Abstract: In response to the dominant logic that characterizes play as frivolous and only marginally relevant, this paper attempts to develop a theoretical framework that will allow play to be taken seriously in organizations. Psychological, sociological, anthropological and philosophical literature streams are reviewed to establish a coherent understanding of the emotional, social and cognitive benefits of play. A net of semantic distinctions is then introduced to differentiate play from work, and play is presented formally as imaginative, ethical and autotelic. This analysis is then embedded in the organizational research literature to show the implications of play with regard to strategic innovation, the management of uncertainty and continuous learning.

The Open Innovation in Science research field: a collaborative conceptualisation approach

Abstract: Openness and collaboration in scientific research are attracting increasing attention from scholars and practitioners alike. However, a common understanding of these phenomena is hindered by disciplinary boundaries and disconnected research streams. We link dispersed knowledge on Open Innovation, Open Science, and related concepts such as Responsible Research and Innovation by proposing a unifying Open Innovation in Science (OIS) Research Framework. This framework captures the antecedents, contingencies, and consequences of open and collaborative practices along the entire process of generating and disseminating scientific insights and translating them into innovation. Moreover, it elucidates individual-, team-, organisation-, field-, and society‐level factors shaping OIS practices. To conceptualise the framework, we employed a collaborative approach involving 47 scholars from multiple disciplines, highlighting both tensions and commonalities between existing approaches. The OIS Research Framework thus serves as a basis for future research, informs policy discussions, and provides guidance to scientists and practitioners.

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.

Abstract: Randomized, double-blind, controlled studies have shown that treatment with risedronate reduces the risk of vertebral fracture in postmenopausal women with established vertebral osteoporosis. They also show that the drug decreases the risk of non-vertebral fractures in women with osteoporosis. The aim of this study was to investigate the cost-effectiveness of risedronate in postmenopausal women with osteoporosis. A Markov model was applied to a UK setting. Treatment effects were computed by meta-analysis of randomized, controlled trials and given over 5 years to subjects aged between 60 and 80 years. Quality-adjusted life years (QALYs) and life years gained were used as outcome measures. Intervention with risedronate was cost-effective in women aged 60 years and older. Cost savings were also found for postmenopausal women aged 70 years and older with established vertebral osteoporosis (a prior spine fracture and BMD T-score ≤−2.5 SD). This treatment was cost-effective for women aged 65 years and older who had a prior vertebral fracture and a BMD T-score at the threshold of osteoporosis (T-score=−2.5 SD), and in women with a T-score≤−2.5 SD, but without a prior vertebral fracture. In women aged 60–80 years and at the threshold of osteoporosis (T-score=−2.5 SD) but without a prior vertebral fracture, treatment exceeded the threshold for cost-effectiveness. However, if an additional, independent risk factor was assumed (e.g., corticosteroid use) treatment became cost-effective.